• Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset Realasset
moneycontrol.com

Home » News » Business

Jan 02, 2013, 09.15 AM | Source: PTI

Aurobindo gets USFDA nod for anti-migraine tablets

Drug maker Aurobindo Pharma Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Like this story, share it with millions of investors on M3

Aurobindo gets USFDA nod for anti-migraine tablets

Drug maker Aurobindo Pharma Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Post Your Comments

Share Cancel

Drug maker Aurobindo Pharma Ltd today said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Rizatriptan Benzoate Tablets used in the treatment of migraine.

Also read: FMCG, pharma stocks hog limelight as defensive bets

The product which was tentatively approved by the FDA earlier, is ready for launch, a statement from Aurobindo said.

Rizatriptan Benzoate Tablets 5mg (base) and 10mg (base) is the generic equivalent of Merck and Co's Maxalt Tablets of equivalent dose and is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old.

The annual sale of the product is approximately USD 300 million for 12 months ending March 2012 according to IMS data, the release said.

The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad.

Aurobindo now has a total of 171 abbreviated new drug application (ANDA) approvals (146 Final approvals including 2 from Aurolife Pharma LLC and 25 Tentative approvals) from USFDA, according to Aurobindo.

Aurobindo scrip is traded at Rs 193.25 apiece on BSE in the afternoon trade.

Aurobindo Pharm stock price

On February 11, 2016, Aurobindo Pharma closed at Rs 641.60, down Rs 50.15, or 7.25 percent. The 52-week high of the share was Rs 891.50 and the 52-week low was Rs 490.50.


The company's trailing 12-month (TTM) EPS was at Rs 26.48 per share as per the quarter ended December 2015. The stock's price-to-earnings (P/E) ratio was 24.23. The latest book value of the company is Rs 94.54 per share. At current value, the price-to-book value of the company is 6.79.

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Aurobindo gets USFDA nod for anti-migraine tablets

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login